Abstract:Acute kidney injury leading to chronic kidney disease through tubulointerstitial fibrosis is a major challenge in nephropathy. Several signaling pathways promote interstitial fibrosis; however, effective suppression of fibrosis may require blockade of more than one pathway. This study investigated whether blockade of Smad3 and c-Jun N-terminal kinase (JNK) signaling gives added suppression of interstitial fibrosis in folic acid nephropathy. A single high dose of folic acid (FA) causes acute tubular damage in C57BL/6J mice followed by interstitial fibrosis and chronic renal impairment. Co-activations of Smad3 and JNK signaling occur in both tubular epithelial cells and myofibroblasts in areas of tubulointerstitial damage and fibrosis in both murine FA-induced nephropathy and human IgA nephropathy. Groups of mice were treated with a Smad3 inhibitor (SIS3), a JNK inhibitor (SP600125), or a combination from day 6 after FA administration until being killed on day 28. Each drug efficiently inhibited its specific target (Smad3 phosphorylation or c-Jun phosphorylation) without affecting the other pathway. Given alone, each drug partially reduced renal fibrosis, whereas the combination therapy gave an additive and profound protection from renal fibrosis and improved renal function. Inhibition of Smad3 and/or JNK signaling activities prevented down-regulation of PGC-1α in tubular epithelial cells and up-regulation of PGC-1α in myofibroblasts during FA-induced renal fibrosis and inflammation. The expression of PGC-1α was upregulated in Smad3 -/- NRK52E cells while downregulated in Smad3 -/- NRK49F cells, suggesting that Smad3 signaling may regulate expression of PGC-1α in renal tubular epithelial cells and fibroblasts in distinct fashion. In vivo and cell culture studies also indicate that Smad3 and JNK signaling cooperate to cause mitochondrial dysfunction and cell damage in tubular epithelial cells via direct actions on the transcription of PGC-1α. These pathways also act cooperatively to promote renal fibroblast proliferation in tempo-spatial fashion. In conclusion, we have identified a potential combination therapy for progressive renal fibrosis which operates, in part, through modifying mitochondrial function.

Pharmacological Inhibition of STAT6 Ameliorates Myeloid Fibroblast Activation and Alternative Macrophage Polarization in Renal Fibrosis

STAT6 Deficiency Attenuates Myeloid Fibroblast Activation and Macrophage Polarization in Experimental Folic Acid Nephropathy

Pharmacologic Inhibiting STAT3 Delays the Progression of Kidney Fibrosis in Hyperuricemia-Induced Chronic Kidney Disease.

Blocking Interleukin-6 Trans-Signaling Protects Against Renal Fibrosis by Suppressing STAT3 Activation

A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy.

Pharmacological Inhibition of STING/TBK1 Signaling Attenuates Myeloid Fibroblast Activation and Macrophage to Myofibroblast Transition in Renal Fibrosis

STAT6 contributes to renal fibrosis by modulating PPARα-mediated tubular fatty acid oxidation

Combined Blockade of Smad3 and JNK Pathways Ameliorates Progressive Fibrosis in Folic Acid Nephropathy

Targeting C-Fms Kinase Attenuates Chronic Aristolochic Acid Nephropathy in Mice.

Inhibition of STAT3 Acetylation is Associated with Attenuated Renal Fibrosis in the Obstructed Kidney

Histone deacetylase 6 inhibition mitigates renal fibrosis by suppressing TGF- and EGFR signaling pathways in obstructive nephropathy

Pharmacological Targeting Macrophage Phenotype Via Gut-Kidney Axis Ameliorates Renal Fibrosis in Mice.

Inhibition of Jak/STAT signaling ameliorates mice experimental nephrotic syndrome.

Targeted inhibition of TGF-β type I receptor by AZ12601011 protects against kidney fibrosis

Pharmacological Inhibition of S100A4 Attenuates Fibroblast Activation and Renal Fibrosis

Empagliflozin reduces kidney fibrosis and improves kidney function by alternative macrophage activation in rats with 5/6-nephrectomy

Treatment of renal interstitial fibrosis with an agonistic Tie2 monoclonal antibody via amelioration of peritubular capillary lesions in a mouse model of nephropathy

Myeloid-specific Targeting of Notch Ameliorates Murine Renal Fibrosis Via Reduced Infiltration and Activation of Bone Marrow-Derived Macrophage

Inhibition of STAT6 Activation by AS1517499 Inhibits Expression and Activity of PPARγ in Macrophages to Resolve Acute Inflammation in Mice

Astaxanthin Protects Against Renal Fibrosis Through Inhibiting Myofibroblast Activation and Promoting CD8+ T Cell Recruitment.

Reduction of Renal Interstitial Fibrosis by Targeting Tie2 in Vascular Endothelial Cells